15085-43-5

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 106-53-6 para-bromobenzenethiol 
• 934-71-4 1-bromo-4-(methylsulfinyl)benzene 

Downstream Products

• 15115-76-1 4-[(4-bromophenyl)thio]butanoic acid 
• 15084-55-6 7-bromo-3,4-dihydro-1-benzothiepin-5(2H)-one 
• 677707-97-0 7-(4-methylphenyl)-3,4-dihydro-1-benzothiepin-5(2H)-one 
• 279263-09-1 methyl 7-(4-methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylate 
• 677707-98-1 methyl 7-(4-methylphenyl)-5-oxo-2,3,4,5-tetrahydro-1-benzothiepine-4-carboxylate 
• 259739-46-3 7-(4-methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylic acid 
• 279261-59-5 methyl 7-(4-methylphenyl)-2,3-dihydro-1-benzothiepine-4-carboxylate 1,1-dioxide 
• 279261-60-8 7-(4-methylphenyl)-1,1-dioxo-2,3-dihydro-1-benzothiepine-4-carboxylic acid 
• 229005-68-9 7-(4-methylphenyl)-N-(4-{[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-2,3-dihydro-1-benzothiepine-4-carboxamide 

Relevant academic research and scientific papers

Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists

Quaternary ammonium benzocycloheptene compound 1 has previously been reported as a clinical candidate for an injectable CCR5 antagonist. In order to develop an orally active CCR5 antagonist, derivatives of tertiary amine benzocycloheptene 2, the chemical precursor to 1, were investigated. The benzocycloheptene ring was converted to benzothiepine and benzazepine rings and it was found that these changes could enhance the potency of tertiary amine derivatives. In particular, the 1-benzothiepine-1,1-dioxide 11b and the N-methyl-1-benzazepine 18 showed increased activity and good preliminary pharmacokinetic properties. The synthesis of 1-benzothiepine and 1-benzazepine derivatives and their activity are described.

Sulfoxide Reduction/C(sp3)-S Metathesis Cascade in Ionic Liquid

A sulfoxide reduction/C-S bond metathesis cascade between sulfoxides and alkyl bromides has been developed to access high-value sulfides without the use of any catalysts or bases. In this cascade, classical Kornblum oxidation is employed to reduce sulfoxides with alkyl bromides in ionic liquid. This protocol features high functional tolerance, mild conditions, promising scalability, and sustainable solvents.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.